Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?
作者信息
Amjad Waseem, Malik Adnan
机构信息
Department of Internal Medicine, Albany Medical Center, Albany, New York, USA.
Hepatology, Loyola University Medical Center, Maywood, Illinois, USA.
出版信息
Am J Gastroenterol. 2021 Jul 1;116(7):1561. doi: 10.14309/ajg.0000000000001217.
Abstract
摘要
相似文献
1
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?法莫替丁与住院的新冠病毒肺炎患者：益处是真的吗？
Am J Gastroenterol. 2021 Jul 1;116(7):1561. doi: 10.14309/ajg.0000000000001217.
2
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.法莫替丁使用与新型冠状病毒肺炎患者临床结局之间的关联：现有证据评估
Am J Gastroenterol. 2021 Apr;116(4):848-849. doi: 10.14309/ajg.0000000000001008.
3
Famotidine and Mortality in Coronavirus Disease 2019.法莫替丁与2019冠状病毒病死亡率
Gastroenterology. 2021 Jul;161(1):361-362. doi: 10.1053/j.gastro.2020.12.045. Epub 2020 Dec 31.
4
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.法莫替丁在 2019 年新型冠状病毒疾病中的再利用：系统评价。
Drug Res (Stuttg). 2021 Jul;71(6):295-301. doi: 10.1055/a-1397-6763. Epub 2021 Mar 23.
5
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.法莫替丁的使用与 COVID-19 患者重症病程风险：一项荟萃分析
Mayo Clin Proc. 2021 May;96(5):1365-1367. doi: 10.1016/j.mayocp.2021.03.001. Epub 2021 Mar 5.
6
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.回复——法莫替丁的使用与新冠肺炎患者重症病程风险：一项荟萃分析。
Mayo Clin Proc. 2021 May;96(5):1367-1368. doi: 10.1016/j.mayocp.2021.03.002. Epub 2021 Mar 5.
7
Histamine receptors and COVID-19.组胺受体与 COVID-19。
Inflamm Res. 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18.
8
Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis.法莫替丁对 COVID-19 住院患者的影响：系统评价和荟萃分析。
PLoS One. 2021 Nov 4;16(11):e0259514. doi: 10.1371/journal.pone.0259514. eCollection 2021.
9
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.法莫替丁能否降低新冠病毒肺炎患者进展为重症疾病、死亡及插管的风险？一项系统评价与Meta分析
Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.
10
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.法莫替丁治疗新冠病毒病的临床疗效无证据：一项系统评价和荟萃分析。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.022. Epub 2022 Dec 1.
引用本文的文献
1
Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients.组胺2受体拮抗剂不能改善住院的2019冠状病毒病患者的治疗结果。
Prz Gastroenterol. 2022;17(2):146-151. doi: 10.5114/pg.2021.107799. Epub 2021 Jul 14.
Zotero 插件